Companies Dominating the Cytokine Landscape
- Sanofi
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- AbbVie Inc
- UCB S.A
- Novartis AG
- Pfizer Inc.
- Biocon Limited
- Amgen Inc
- GlaxoSmithKline PLC
- General Electric Company
- Johnson & Johnson
Browse Key Market Insights with Data Illustration:
In the News
- Sanofi reported that the additional Biologics License Application for Dupixentundupilumab to be used in adults with prurigo nodularis, a chronic inflammation skin disease causing extreme itch and lesions has been given priority review by the United States Food and Drug Administration. Dupixent is a fully Human Monoclonal Antibodies that inhibit the signaling of Interleukin 4 and Interleukin 13 pathways, which are not immunosuppressants.
- Sandoz, a global leader in generic and biosimilar medicines, announced that the US Food and Drug Administration has accepted for review its supplemental Biologics License Application for a high concentration formulation of 100 mg mLHCF of its biosimilar Hyrimoz. The application includes the indications of the reference medicine Humira not protected by orphan exclusivity, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis.
